These experiments, along with broader cohort analyses, would help reconcile conflicting findings in the literature and clarify how miR‐100 and miR‐101 modulate the mTOR/AKT/PI3K axis in different AML contexts. The gene discussed is AKT1; the disease is acute myeloid leukemia.